Lonza Significantly Expands Biologics Manufacturing Capacity by Over 200,000 Liters with New Swiss Facility

Lonza Press Release Switzerland

Overview

Lonza announced the operational launch of a state-of-the-art new facility in Visp, Switzerland, significantly expanding its biopharmaceutical manufacturing capabilities. This expansion adds over 200,000 liters of total capacity to meet increasing demand for mammalian and microbial biopharmaceutical production, including advanced modalities like monoclonal antibodies and fusion proteins. This investment strengthens Lonza’s leadership in the CDMO market and supports clients’ global supply chain resilience.

In Depth

Key Findings

Lonza, a global Contract Development and Manufacturing Organization (CDMO), has announced the operational launch of its state-of-the-art new facility in Visp, Switzerland, significantly expanding its biopharmaceutical manufacturing capacity. This strategic expansion adds over 200,000 liters of total manufacturing volume to address the growing demand for mammalian cell-based and microbial fermentation-based biopharmaceutical production, including advanced modalities.

Technical / Clinical Details

The new facility in Visp features multiple independent manufacturing suites, integrating the latest single-use technologies and process automation. This enables it to support cGMP (current Good Manufacturing Practice) manufacturing of a wide range of biologics, including monoclonal antibodies (mAbs), antibody-drug conjugate (ADC) intermediates, fusion proteins, and other recombinant proteins. Specifically, the mammalian cell culture capacity includes multiple bioreactors ranging from 2,000-liter to 20,000-liter scale, allowing for flexible production volumes. Microbial fermentation capabilities have also been enhanced, enabling high-titer protein production. The quality control systems are also state-of-the-art, ensuring compliance with stringent customer requirements.

Background & Context

The biopharmaceutical market continues to experience robust growth driven by advancements in therapies for cancer, autoimmune diseases, and rare disorders. The demand for flexible and large-scale CDMO services has surged, particularly with the emergence of new modalities and the urgent need for rapid production capacity in response to pandemics. Lonza has long been recognized as a leader in biopharmaceutical manufacturing, and this expansion represents a critical investment to maintain its market dominance and support clients’ pipeline development.

Strategic Significance & Outlook

The operationalization of the new Visp facility underscores Lonza’s commitment to further strengthening its central role in the global biopharmaceutical supply chain. This added manufacturing capacity will enable clients to bring complex biologics to market more quickly and efficiently, ultimately contributing to delivering life-saving medicines to more patients worldwide. Lonza will continue to address future needs in biopharmaceutical manufacturing through sustained technological innovation and capacity expansion, significantly contributing to the overall growth of the CDMO industry and improving access to biological therapies.